Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBT Margin (2023 - 2026)

Entrada Therapeutics has reported EBT Margin over the past 3 years, most recently at 3007.85% for Q4 2025.

  • For Q4 2025, EBT Margin fell 300592.0% year-over-year to 3007.85%; the TTM value through Dec 2025 reached 561.84%, down 59339.0%, while the annual FY2025 figure was 561.84%, 59339.0% down from the prior year.
  • EBT Margin for Q4 2025 was 3007.85% at Entrada Therapeutics, down from 2693.93% in the prior quarter.
  • Over five years, EBT Margin peaked at 61.03% in Q2 2024 and troughed at 3007.85% in Q4 2025.
  • A 3-year average of 665.19% and a median of 39.43% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: skyrocketed 12752bps in 2024 and later plummeted -300592bps in 2025.
  • Year by year, EBT Margin stood at 21.98% in 2023, then plummeted by -109bps to 1.94% in 2024, then crashed by -155270bps to 3007.85% in 2025.
  • Business Quant data shows EBT Margin for TRDA at 3007.85% in Q4 2025, 2693.93% in Q3 2025, and 2201.28% in Q2 2025.